Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;17(7):931-936.
doi: 10.1016/j.jtho.2022.03.018. Epub 2022 Apr 27.

The 2021 Global Lung Cancer Therapy Landscape

Dhruba Deb  1 , Amy C Moore  2 , Upal Basu Roy  3
Affiliations
Free article

The 2021 Global Lung Cancer Therapy Landscape

Dhruba Deb et al. J Thorac Oncol. 2022 Jul.
Free article

Abstract

Introduction: The lung cancer treatment landscape has substantially evolved over the past decade. However, a systematic analysis of the current global drug development landscape has not been conducted.

Methods: We curated and analyzed a comprehensive list of therapeutic entities (TEs) in preclinical development and clinical trials for lung cancer.

Results: On the basis of our analysis of 707 TEs, we found a consistent forward trajectory in the development pipeline for both NSCLC and SCLC. Most of the TEs were in the advanced stages of clinical trials. Targeted therapies continue to dominate in the non-immuno-oncology space. Immuno-oncology targets are expanding beyond inhibitors of the programmed death-ligand 1 axis.

Conclusions: Our analysis highlights a robust portfolio of both preclinical and clinical TEs and suggests that lung cancer treatment is going to become even more biomarker-driven.

Keywords: Clinical trials; Non–small cell lung cancer; Preclinical research; Small cell lung cancer.

PubMed Disclaimer

Comment in

MeSH terms